I2I Phase I: A Portable Blood Group Typing Analyzer

I2I 第一阶段：便携式血型分型分析仪

• 批准号: 566842-2021
• 负责人: Wheeler, Aaron
• 金额: $ 9.11万
• 依托单位: University of Toronto
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=728736
• 关键词: I2I; Phase; Portable; Blood; Group

Hemorrhage is the third leading cause of death among trauma patients. A transfusion is needed to replenish the patient's lost blood; however, prior to transfusion, physicians must determine the patient's blood type to administer blood from a compatible donor. In high stakes environments such as a trauma setting every second is critical and therefore doctors are in need for fast and reliable methods to monitor the hemorrhaging patient. Currently, hospitals rely on large batch processing systems, dedicated to each test or subset of tests (e.g. blood-grouping and hematological tests), which introduce large delays between the sample collection and the results' release. While physicians wait for these results, they must use universal blood products that are in short supply. To address this issue, the microfluidics community has developed point-of-care tests, but those that have made it to market have not been adopted because of errors caused by manual processing and analysis "by eye." This proposal aims to prove the concept of an autonomous, low-cost blood analyzer, used to provide healthcare professionals with access to real time and reliable results. The solution described here is based on an advanced liquid handling technology, called digital microfluidics (DMF), which uses an array of electrodes to manipulate discrete droplets. DMF enables complete automation of blood group testing, with results that are in 100% concordance with the gold standard method. The results are available in 6 minutes from a shoebox sized, battery-powered instrument that can be operated at the point of care. This I2I Phase 1 grant will allow us to explore options to bring the cost of consumable cartridges down to competitive levels, as a step toward commercialization. We envision that this platform will become an essential medical monitoring device for physicians that seek fast and reliable blood analyses at the point of care, helping them provide best-in-class care for Canadians and others around the world.

出血是创伤患者死亡的第三大主要原因。需要输血来补充患者的血液损失；但是，在输血之前，医生必须确定患者的血型以从兼容的供体中施用血液。在高赌注环境中，例如每秒创伤设置至关重要，因此医生需要快速可靠的方法来监测出血患者。当前，医院依靠大型批处理系统，专门用于每个测试或测试子集（例如，血管组和血液学测试），这些系统在样本收集和结果的发布之间引入了较大的延迟。当医生等待这些结果时，他们必须使用短暂供应的通用血液产品。为了解决这个问题，微流体社区已经开发了护理点测试，但是那些已经在市场上的人没有通过手动处理和分析“通过眼睛”而被采用的。该建议旨在证明一种自主，低成本的血液分析仪的概念，用于为医疗保健专业人员提供实时和可靠的结果。此处描述的解决方案基于一种称为数字微流体（DMF）的先进液体处理技术，该技术使用一系列电极来操纵离散液滴。 DMF实现了血型测试的完全自动化，结果与黄金标准方法100％一致。结果可在6分钟内从可以在护理点上操作的鞋盒大小的，电池供电的仪器提供。这项I2i第1阶段赠款将使我们能够探索选项，以将易于墨盒的成本降低到竞争水平，以迈向商业化。我们设想，该平台将成为医生的重要医疗监测设备，这些医师在护理时期寻求快速可靠的血液分析，帮助他们为加拿大人和世界各地的其他人提供一流的护理。